Overview
- The stock, which hit a 20% upper circuit to about Rs 432 on the NSE on Monday, rose again the next session to roughly Rs 510 in early trade.
- Cohance said Vohra will start as executive chairman on May 1 and take over as group CEO on May 20.
- He succeeds Vivek Sharma, who is stepping down for personal reasons and will stay on as an advisor for nine months to help the handover.
- Majority investor Advent International said Vohra brings an owner‑manager mindset and operational depth that can drive commercial scale and deeper customer ties.
- Cohance runs a contract development and manufacturing platform focused on complex chemistry work such as antibody‑drug conjugates, oligonucleotides and advanced APIs, supported by integrated R&D centers and more than 400 scientists.